SangStat completes Phase II/III GvHD enrollment

SANG completed enrollment in an international Phase II/III study comparing ABX-CBL to Atgam anti-thymocyte globulin in treating steroid-resistant graft-versus-host disease (GvHD) in allogeneic bone ma...